Clearmind Medicine Inc. (CMND)

CA — Healthcare Sector
Peers: HILS  COEP  MGTA  QNRX  CDIO  WINT  NBY  BXRX  REVB  BWV  PXMD  UNCY  VRAX  IMMX  CNSP  EFTR  NAVB  SONN 

Automate Your Wheel Strategy on CMND

With Tiblio's Option Bot, you can configure your own wheel strategy including CMND - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol CMND
  • Rev/Share 0.0
  • Book/Share 0.6358
  • PB 1.5131
  • Debt/Equity 0.0161
  • CurrentRatio 1.7224
  • ROIC -2.2554

 

  • MktCap 4939663.0
  • FreeCF/Share -1.0405
  • PFCF -1.0576
  • PE -0.8708
  • Debt/Assets 0.007
  • DivYield 0
  • ROE -1.4087

 

  • Rating B-
  • Score 2
  • Recommendation Sell
  • P/E Score 1
  • DCF Score 4
  • P/B Score 3
  • D/E Score 4

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
No ratings available.

News

Clearmind Medicine's FDA-Approved Clinical Trial for CMND-100 Moves Forward as Drug Arrives in the U.S., Advancing Toward Key Milestones
CMND
Published: March 21, 2025 by: GlobeNewsWire
Sentiment: Neutral

Vancouver, Canada, March 21, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, announced today that its innovative drug candidate, CMND-100, has arrived in the United States following successful manufacturing. This marks a key milestone as the Company prepares to initiate its FDA-approved Phase I/IIa clinical trial for the treatment of Alcohol Use Disorder (AUD), a condition affecting over 28 million adults in the U.S. alone.

Read More
image for news Clearmind Medicine's FDA-Approved Clinical Trial for CMND-100 Moves Forward as Drug Arrives in the U.S., Advancing Toward Key Milestones

About Clearmind Medicine Inc. (CMND)

  • IPO Date 2022-11-15
  • Website https://www.clearmindmedicine.com
  • Industry Biotechnology
  • CEO Dr. Adi Zuloff-Shani Ph.D.
  • Employees 4
Clearmind Medicine Inc., a pre-clinical pharmaceutical company, develops novel psychedelic medicines to treat under-served health problems. It develops treatments for alcohol use disorders, including binge drinking and eating disorders, as well as depression, binge eating, psychotherapy, mental health issues, and other binge behaviors. The company was formerly known as Cyntar Ventures Inc. and changed its name to Clearmind Medicine Inc. in March 2021. Clearmind Medicine Inc. was incorporated in 2017 and is based in Vancouver, Canada.